Clinical Trials Logo

Relapsed/Refractory B-cell ALL clinical trials

View clinical trials related to Relapsed/Refractory B-cell ALL.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03391739 Recruiting - Clinical trials for Relapsed/Refractory B-cell ALL

CART-19 Cells For R/R B-ALL

CCFRRBA
Start date: January 2016
Phase: Phase 2/Phase 3
Study type: Interventional

There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.